Replies to post #80443 on Biotech Values

[genisi]

Will D-Mab Be Better Than Zometa in Prostate Cancer?

I think it will for a couple of reasons:
The level of bone turnover is the highest in prostate cancer and since denosumab strongly inhibits osteoclasts, which are the main driver for SREs there, I'd expect it to be efficient in preventing SREs in this setting. One more point is - D-mab should also delay/reduce bony metastasis for the same reason (plus prostate cancer cells primarily metastasize to the bone), and if so, it is going to be a touchdown (big unmet need and Zometa has not been shown to prevent the formation of bony metastases). Other parameters like safety and subQ vs infusion might also help.
I'm quite sure denosumab will be non inferior to Zometa and optimistic it will even be superior.